Compare Ecopetrol SA (EC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Zimmer Biomet Holdings Inc — how do they compare? Ecopetrol SA trades at $17.01 (market cap $33.11B), while Zimmer Biomet Holdings Inc trades at $89.33 (market cap $16.95B). The key difference: Ecopetrol SA is the larger of the two by market cap, and Ecopetrol SA pays the higher dividend (3.83%). Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| EC | ZBH | |
|---|---|---|
Market Cap | $33.11B | $16.95B |
Volume | 993,598 | 2,505,240 |
Sector | Energy | Health |
52-Week High | $18.26 | $103.98 |
52-Week Low | $8.61 | $79.58 |
Typical Hold Time | 84 Days | 89 Days |
Enterprise Value | $61.36B | $24.02B |
Dividend Yield | 3.83% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $17.07, up 2.65% on the day, but faces a bearish technical signal with recent earnings misses. Revenue declined to $119.69T in 2025, with net income margin at 8.76%, though profitability metrics like ROE (17.67%) remain solid. The company is undergoing senior management changes amid government-led board restructuring, creating uncertainty.
The outlook is mixed: low valuations (P/E 7.97, EV/EBITDA 4) suggest potential upside, but declining revenue, earnings volatility, and political interference pose significant risks. Analyst consensus is cautious with a $16.85 price target below current levels, indicating limited near-term catalysts for substantial growth.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
